期刊文献+

复发性卵巢癌患者术后血清CA125、D-D水平及残留病灶大小对无瘤生存期的影响

Effects of Serum CA125,D-D Levels and Residual Lesion Size on Tumor-free Survival in Patients with Recurrent Ovarian Cancer After Surgery
下载PDF
导出
摘要 目的 探讨复发性卵巢癌患者术后血清糖链抗原125(CA125)、D-二聚体(D-D)水平及残留病灶大小对无瘤生存期的影响。方法 回顾性分析50例复发性卵巢癌患者的临床资料,随访并记录无瘤生存期。统计患者一般资料及术后血清CA125、D-D水平,分析无瘤生存期影响因素;以Pearson相关系数分析术后CA125、D-D水平及残留病灶大小与无瘤生存期的相关性。结果 不同临床分期、分化程度、化疗疗程、CA125、D-D水平及残留病灶大小的患者无瘤生存期比较,差异有统计学意义(P<0.05);COX回归分析显示,术前临床分期、术后CA125水平、术后D-D水平及术后残留病灶大小是复发性卵巢癌患者无瘤生存期的独立影响因素(P<0.05);Pearson相关性分析显示,术后CA125、D-D水平及残留病灶大小与无瘤生存期均呈负相关(P<0.05)。结论 复发性卵巢癌患者术后CA125、D-D水平及残留病灶大小是影响其无瘤生存期的重要因素。 Objective To explore the effects of serum carbohydrate antigen 125(CA125),D-Dimer(D-D)levels and residual lesion size on tumor-free survival in patients with recurrent ovarian cancer after surgery.Methods The clinical data of 50 patients with recurrent ovarian cancer were retrospectively analyzed,and the disease-free survival time was followed up and recorded.General data and postoperative serum CA125 and D-D levels of patients were analyzed,factors influencing disease-free survival were analyzed.Pearson correlation coefficient was used to analyze the correlation between postoperative CA125,D-D levels,residual lesion size and tumor-free survival.Results Tumor free survival of patients with different clinical stage,differentiation degree,chemotherapy course,CA125,D-D level and residual lesion size were statistically significant(P<0.05).COX regression analysis showed that preoperative clinical stage,postoperative CA125 level,postoperative D-D level and postoperative residual lesion size were independent influencing factors for tumor free survival of patients with recurrent ovarian cancer(P<0.05).Pearson correlation analysis showed that postoperative CA125,D-D levels and residual lesion size were negatively correlated with tumor-free survival(P<0.05).Conclusion Postoperative CA125 and D-D levels and residual lesion size are important factors affecting tumor free survival in patients with recurrent ovarian cancer.
作者 孙慧霞 许静 郭哲 梁殿迅 SUN Huixia;XU Jing;GUO Zhe(Nanyang Central Hospital,Nanyang,473000)
出处 《实用癌症杂志》 2024年第7期1175-1178,1182,共5页 The Practical Journal of Cancer
关键词 复发性卵巢癌 无瘤生存期 糖链抗原125 D-二聚体 残留病灶大小 Recurrent ovarian cancer Disease-free survival Carbohydrate antigen 125 D-Dimer Residual lesion size
  • 相关文献

参考文献8

二级参考文献64

  • 1韦佩佳.老年复发卵巢癌患者预后影响因素[J].中国老年学杂志,2014,34(8):2081-2082. 被引量:10
  • 2Hennessy BT, Coleman RL, Maurie M. Ovarian cancer [ J ]. Lancet, 2009,374 (9698) : 1371 - 1382.
  • 3Ushijima K. Treatment for recurrent ovarian cancer-at first relapse. [ J ]. Journal of Oncology, 2010, 2010: 497429. DOI: 10. 1155/ 2010/497429.
  • 4Musella A, Marchetti C, Palaia I, et al. Secondary cytoreduction in platinum-resistant recurrent ovarian cancer: A single-institution expe- rience[ J]. Annals of Surgical Oncology,2015,22(13) :4211 -4216.
  • 5Chee Khoon L, Sarah L,Tami G, et al. Impact of secondary cytoreduc- tive surgery on survival in patients with platinum sensitive recurrent o- varian cancer:analysis of the CALYPSO trial [J]. Gynecologic Oncol- ogy,2015,136( 1 ) :18 -24.
  • 6Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovari- an cancer: A meta-analysis [ J ]. Gynecologic Oncology, 2009,112 ( 1 ) :265 -274.
  • 7Tian W,Jiang R, Cheng X, et al. Surgery in recurrent epithelial ovari- an cancer: benefits on survival for patients with residual disease of 0. 1 - 1 cm after secondary cytoreduction [ J ]. Journal of Surgical On- cology ,2010,101 ( 3 ) :244 - 250.
  • 8Brun JFL, Loic Campion MD,Dominique Berton-Rigaud MD,et al. Survival benefit of hyperthermic intraperitoneal chemotherapy for re- current ovarian cancer : a multi-institutional case control study [J]. Annals of Surgical Oncology ,2014,21 ( 11 ) :3621 - 3627.
  • 9刘宝莲,韩萍.卵巢上皮性癌复发的相关因素研究[J].中国妇幼保健,2013,28(20):3250-3254. 被引量:12
  • 10孙丽丽,贾薇,常彬.卵巢癌化疗耐药机制研究进展[J].临床与实验病理学杂志,2013,29(11):1229-1231. 被引量:11

共引文献92

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部